Holen Sie sich die Stockscreener-App
8.69
3.58%
0.30
Handel nachbörslich:
8.65
-0.04
-0.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.39
Offen:
$8.38
24-Stunden-Volumen:
2.95M
Relative Volume:
0.59
Marktkapitalisierung:
$1.42B
Einnahmen:
$1.12B
Nettoeinkommen (Verlust:
$440.30M
KGV:
3.6505
EPS:
2.3805
Netto-Cashflow:
$-251.02M
1W Leistung:
+3.21%
1M Leistung:
-15.10%
6M Leistung:
-2.47%
1J Leistung:
+35.99%
1-Tages-Spanne:
$8.38
$8.7861
1-Wochen-Bereich:
$7.99
$8.7861
52-Wochen-Spanne:
$5.80
$11.97
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.69 | 1.37B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Discipline and Rules-Based Execution in NVAX Response - Stock Traders Daily
Novavax Inc stock (US6707721049): Is its vaccine pipeline strong enough to unlock new upside? - AD HOC NEWS
SHAH CAPITAL MANAGEMENT Increases Stake in Novavax Inc - GuruFocus
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Inc stock (US6707721049): Is its vaccine pivot strong enough to unlock new upside? - AD HOC NEWS
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
Synlogic and Novavax Face Off in Financial Analysis - National Today
Novavax, Inc. Revenue Breakdown – BSESOF:NVV1 - TradingView — Track All Markets
Why Novavax (NVAX) Is Up 5.5% After Activist Pressure Meets New R&D Leadership And What's Next - Yahoo Finance
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Novavax (NVAX) Being Pulled Between R&D Ambitions and Activist Demands for Discipline? - simplywall.st
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
US CDC delays publishing report showing COVID vaccine benefits, WaPo reports - Reuters
B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating - marketscreener.com
Novavax (NVAX) Receives a Sell from Bank of America Securities - The Globe and Mail
Shah Capital Pushes for Changes at Novavax (NVAX) - GuruFocus
Why is NVAX stock surging today? - MSN
Shah Capital Blasts Novavax Strategy In New Letter To Board - Citeline News & Insights
Shah Capital's Plan to Vote Against Novavax Board Nominees | PharmExec - Pharmaceutical Executive
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees - Pharmaceutical Executive
Investor calls for Novavax to slash costs, cut board as vaccine sales disappoint - The Business Journals
Shah Capital intends to vote against Novavax's board nominees, executive compensation - Reuters
Activist investor revives campaign to overhaul Novavax board - BioPharma Dive
Novavax Faces Shareholder Revolt As Shah Capital Criticizes StrategyNovavax (NASDAQ:NVAX) - Benzinga
3 Reasons NVAX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Novavax rises as Shah Capital calls for changes (NVAX:NASDAQ) - Seeking Alpha
Assessing Novavax (NVAX) Valuation After Renewed Focus On Covid And Malaria Vaccine Deals - Yahoo Finance
Novavax stock surges as activist pushes for board changes By Investing.com - Investing.com Canada
Why Is NVAX Stock Surging Today? - Stocktwits
Shah Capital (NVAX) discloses 9.11% Novavax stake and plans votes against board - Stock Titan
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Is Novavax (NVAX) A Potential Opportunity After Recent Share Price Weakness - Yahoo Finance
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX) - MarketBeat
Levels Update: Is Novavax Inc benefiting from interest rate changes2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Novavax, Inc. (NVAX) stock price, news, quote and history - Yahoo Finance UK
Behavioral Patterns of NVAX and Institutional Flows - Stock Traders Daily
Novavax Inc stock: Biotech innovator or fading COVID play? - AD HOC NEWS
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Shares Down 5.4%Should You Sell? - MarketBeat
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Investors heavily search Novavax, Inc. (NVAX): Here is what you need to know - MSN
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax (XTER:NVV1) PB Ratio : (As of Mar. 31, 2026) - GuruFocus
New Novavax R&D Leader Raises Questions On Valuation Gap And Outlook - Yahoo Finance
Shah Capital Management Purchases 2,747,000 Shares of Novavax, Inc. $NVAX - MarketBeat
Novavax names Robert Walker as R&D head By Investing.com - Investing.com South Africa
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):